Evidence map›Paper›PMID 35324910›Full record

Trial reportPLoS medicine2022

Prevention of violence against women and girls: A cost-effectiveness study across 6 low- and middle-income countries.

Giulia Ferrari, Sergio Torres-Rueda, Esnat Chirwa, Andrew Gibbs, Stacey Orangi, Edwine Barasa, Theresa Tawiah, Rebecca Kyerewaa Dwommoh Prah, Regis Hitimana, Emmanuelle Daviaud and 12 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Giulia FerrariLondon School of Economics and Political Science, London, United Kingdom.ORCID 0000-0002-1670-4905
Sergio Torres-RuedaLondon School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0002-6335-6392
Esnat ChirwaGender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.ORCID 0000-0003-0471-4978
Andrew GibbsGender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.ORCID 0000-0003-2812-5377
Stacey OrangiHealth Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.ORCID 0000-0002-3236-5229
Edwine BarasaHealth Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.ORCID 0000-0001-5793-7177
Theresa TawiahKintampo Health Research Centre, Kintampo, Ghana.
Rebecca Kyerewaa Dwommoh PrahKintampo Health Research Centre, Kintampo, Ghana.
Regis HitimanaSchool of Public Health, University of Rwanda, Kigali, Rwanda.
Emmanuelle DaviaudHealth Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.
Eleonah KapapaNational Institute of Public Administration, Lusaka, Zambia.
Kristin DunkleGender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.ORCID 0000-0003-3071-5544
Lori HeiseJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0003-2956-2819
Erin SternLondon School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0001-8800-0176
Sangeeta ChatterjiJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0001-5836-514X
Benjamin OmondiUjamaa Africa, Nairobi, Kenya.
Deda Ogum AlangeaDepartment of Population Family & Reproductive Health, School of Public Health, College of Health Sciences, University of Ghana, Legon, Ghana.ORCID 0000-0001-7496-8514
Rozina KarmalianiDepartment of Community Health Science, Aga Khan University, Karachi, Pakistan.ORCID 0000-0002-9565-5514
Hussain Maqbool Ahmed KhuwajaSchool of Nursing & Midwifery, Aga Khan University, Karachi, Pakistan.
Rachel JewkesGender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.ORCID 0000-0002-4330-6267
Charlotte WattsLondon School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0003-0517-6550
Anna VassallLondon School of Hygiene & Tropical Medicine, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundViolence against women and girls (VAWG) is a human rights violation with social, economic, and health consequences for survivors, perpetrators, and society. Robust evidence on economic, social, and health impact, plus the cost of delivery of VAWG prevention, is critical to making the case for investment, particularly in low- and middle-income countries (LMICs) where health sector resources are highly constrained. We report on the costs and health impact of VAWG prevention in 6 countries. METHODS AND

findingsWe conducted a trial-based cost-effectiveness analysis of VAWG prevention interventions using primary data from 5 randomised controlled trials (RCTs) in sub-Saharan Africa and 1 in South Asia. We evaluated 2 school-based interventions aimed at adolescents (11 to 14 years old) and 2 workshop-based (small group or one to one) interventions, 1 community-based intervention, and 1 combined small group and community-based programme all aimed at adult men and women (18+ years old). All interventions were delivered between 2015 and 2018 and were compared to a do-nothing scenario, except for one of the school-based interventions (government-mandated programme) and for the combined intervention (access to financial services in small groups). We computed the health burden from VAWG with disability-adjusted life year (DALY). We estimated per capita DALYs averted using statistical models that reflect each trial's design and any baseline imbalances. We report cost-effectiveness as cost per DALY averted and characterise uncertainty in the estimates with probabilistic sensitivity analysis (PSA) and cost-effectiveness acceptability curves (CEACs), which show the probability of cost-effectiveness at different thresholds. We report a subgroup analysis of the small group component of the combined intervention and no other subgroup analysis. We also report an impact inventory to illustrate interventions' socioeconomic impact beyond health. We use a 3% discount rate for investment costs and a 1-year time horizon, assuming no effects post the intervention period. From a health sector perspective, the cost per DALY averted varies between US$222 (2018), for an established gender attitudes and harmful social norms change community-based intervention in Ghana, to US$17,548 (2018) for a livelihoods intervention in South Africa. Taking a societal perspective and including wider economic impact improves the cost-effectiveness of some interventions but reduces others. For example, interventions with positive economic impacts, often those with explicit economic goals, offset implementation costs and achieve more favourable cost-effectiveness ratios. Results are robust to sensitivity analyses. Our DALYs include a subset of the health consequences of VAWG exposure; we assume no mortality impact from any of the health consequences included in the DALYs calculations. In both cases, we may be underestimating overall health impact. We also do not report on participants' health costs.

conclusionsWe demonstrate that investment in established community-based VAWG prevention interventions can improve population health in LMICs, even within highly constrained health budgets. However, several VAWG prevention interventions require further modification to achieve affordability and cost-effectiveness at scale. Broadening the range of social, health, and economic outcomes captured in future cost-effectiveness assessments remains critical to justifying the investment urgently required to prevent VAWG globally.

Indexed as

Developing CountriesPovertyAdolescentAdultChildCost-Benefit AnalysisFemaleHumansMaleSouth AfricaViolence

Identifiers

PMID35324910
PMCPMC8946747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.